Welcome to LookChem.com Sign In|Join Free
  • or
2-bromo-N-(3-phenylpropyl)benzamide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

438475-55-9

Post Buying Request

438475-55-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

438475-55-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 438475-55-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,8,4,7 and 5 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 438475-55:
(8*4)+(7*3)+(6*8)+(5*4)+(4*7)+(3*5)+(2*5)+(1*5)=179
179 % 10 = 9
So 438475-55-9 is a valid CAS Registry Number.

438475-55-9Downstream Products

438475-55-9Relevant academic research and scientific papers

Mechanochemical Transformation of CF3 Group: Synthesis of Amides and Schiff Bases

Mkrtchyan, Satenik,Jakubczyk, Micha?,Lanka, Suneel,Yar, Muhammad,Ayub, Khurshid,Shkoor, Mohanad,Pittelkow, Michael,Iaroshenko, Viktor O.

supporting information, p. 5448 - 5460 (2021/10/19)

We communicate two mild, solvent-free mechanochemical coupling transformations of CF3 group with nitro compounds into amides or Schiff bases employing Ytterbia as a catalyst. This process proceeds via C?F bond activation, accompanied with utilisation of Si-based reductants/oxygen scavengers – reductants of the nitro group. The scope and limitations of the disclosed methodologies are thoroughly studied. To the best of our knowledge, this work is the first example of mechanical energy promoted transformation of the inert CF3 group into other functionalities. (Figure presented.).

Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1

Jablonski, Joseph J.,Basu, Dipwanita,Engel, Daniel A.,Geysen, H. Mario

experimental part, p. 487 - 497 (2012/02/15)

Influenza is a continuing world-wide public health problem that causes significant morbidity and mortality during seasonal epidemics and sporadic pandemics. The existing vaccination program is variably effective from year to year, and drug resistance to available antivirals is a growing problem, making the development of additional antivirals an important challenge. Influenza virus non-structural protein 1 (NS1) is the centerpiece of the viral response to the host interferon (IFN) system. NS1 was demonstrated previously to be a potential therapeutic target for antiviral therapy by the identification of specific small-molecule inhibitors. One inhibitory compound, NSC125044, was subjected to chemical evaluation. Initial synthetic work comprised simplifying the core structure by removing unwanted functionality and determination of key features important for activity. Several subclasses of molecules were designed and synthesized to further probe activity and develop the basis for a structure-activity relationship. Apparent potency, as judged by activity in virus replication assays, increased dramatically for some analogs, without cytotoxicity. Results suggest that the target binding site tolerates hydrophobic bulk as well as having a preference for weakly basic substituents.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 438475-55-9